Unicycive Therapeutics 的空头股数上升，但尽管存在怀疑，但分析师仍维持“买入”评级。 Unicycive Therapeutics sees short interest rise, but analysts maintain a "Buy" rating despite the skepticism.

Unicycive Therapeutics 是一家专注于肾脏疾病治疗的生物技术公司，其空头股数在 1 月份上涨了 25.4%，至 124 万股。 Unicycive Therapeutics, a biotech firm focused on kidney disease treatments, saw its short interest rise by 25.4% in January to 1.24 million shares. 尽管如此,该公司还是从分析师那里获得了“Buy”评级,平均目标价格为5.50美元。 Despite this, the company has received a "Buy" rating from analysts with an average target price of $5.50. 与此同时，United Therapeutics 的空头股数下跌了 14.3%，报告收益超出预期每股 0.23 美元。 Meanwhile, United Therapeutics experienced a 14.3% drop in short interest, reporting earnings that surpassed expectations by $0.23 per share.